Ul­tragenyx preps for piv­otal tri­al in An­gel­man syn­drome, an area where oth­ers fell short: #AAN24

Ul­tragenyx is inch­ing clos­er to a Phase 3 study for its An­gel­man syn­drome pro­gram, known as GTX-102.

In a Phase 1/2 up­date Mon­day morn­ing ahead of its Tues­day night pre­sen­ta­tion at the an­nu­al Amer­i­can Acad­e­my of Neu­rol­o­gy meet­ing, Ul­tragenyx was light on da­ta specifics but said a piv­otal tri­al is ex­pect­ed to launch some­time this year. Its stock price $RARE fell by as much as 14% pre­mar­ket but was down about 9% in ear­ly Mon­day trad­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER